Condition
Liver Cirrhoses
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 12 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
12 shownA Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver CirrhosisNCT07291141 · 2025-12-18
RECRUITINGOptimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver DiseaseNCT07058155 · 2025-12-17
RECRUITINGAntibiotic Prophylaxis in Patients Undergoing GVONCT04140578 · 2017-01-28
RECRUITINGHVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic PatientsNCT04254822 · 2020-06-01
UNKNOWNEGD vs EUS in Diagnosing Portal Hypertension in Cirrhotic Patients.NCT04191369 · 2019-11-01
UNKNOWNSimplified Monitoring Myanmar SM2 StudyNCT04113629 · 2019-01-22
COMPLETEDComparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal VaricesNCT03624517 · 2018-09-19
TERMINATEDMRI to Assess the Effect of Terlipressin in Patients With Acute Hepatorenal Syndrome (HRS-AKI)NCT03483272 · 2018-01-08
COMPLETEDThe Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric VaricesNCT03171805 · 2017-06-01
UNKNOWNHemodynamic Alterations in Liver Cirrhosis Validated by Non-invasive MR Compared to Invasive AssessmentNCT03443934 · 2017-04-01
COMPLETEDViatorr CX Case-control Study for Complications of Portal HypertensionNCT03083925 · 2016-05-23
COMPLETEDRole of SWE-change After TIPS in the Prediction of Prognosis After TIPSNCT03072615 · 2013-04-01
COMPLETEDCommon interventions
Anti-Obesity Pharmacotherapy (Class Effect)DRUG1CarvedilolDRUG1Endoscopic ultrasoundDIAGNOSTIC_TEST1Endoscopic variceal ligationPROCEDURE1ErtapenemDRUG1EsophagogastroduodenoscopyDIAGNOSTIC_TEST1HCV point of care machineDEVICE1Lifestyle Counseling - Diet & Physical-Activity ProgramBEHAVIORAL1OctreotideDRUG1PropranololDRUG1Sleeve GastrectomyPROCEDURE1Stiffness measurementDIAGNOSTIC_TEST1TIPSDEVICE1Transjugular intrahepatic portosystemic shuntPROCEDURE1Transjugular Intrahepatic Portosystemic Shunt (TIPS)PROCEDURE1
Leading sponsors
Hvidovre University Hospital
2
Air Force Military Medical University, China
1
Instituto Ecuatoriano de Enfermedades Digestivas
1
Jonel Trebicka
1
Kirby Institute
1
Mattias Ekstedt
1
Medical University of South Carolina
1
Taipei Veterans General Hospital, Taiwan
1
The Cleveland Clinic
1
University Hospital, Bonn
1
West China Hospital
1
Trial status mix
COMPLETED5
RECRUITING3
UNKNOWN3
TERMINATED1
Phase mix
NA4
PHASE43
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.